Clarity Pharmaceuticals Ltd has released a press release.
DISCO topline results
Filed with ASX ·
6ix hasn’t read this filing yet.
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- First patient imaged in Phase III AMPLIFY trial with 64Cu-SAR-bisPSMA PET/CT
- First patient imaged in Phase III AMPLIFY trial
- Registrational Phase III AMPLIFY trial in biochemical recurrence of prostate cancer commences
- AMPLIFY trial commences
- Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano
Later from Clarity Pharmaceuticals
- DISCO topline results: 64Cu-SARTATE is highly effective in detecting tumours in NET patients compared to SOC imaging. Phase III planning underway.
- SABRE topline results
- SABRE topline results: Cu-64 SAR-Bombesin is effective in detecting prostate cancer recurrence in patients with negative SOC imaging
- Clarity enters a Commercial Manufacturing Agreement
- Clarity enters a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals